Assessment of Bone Micro-Architecture Using HR-pQCT

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-30

Study Completion Date

2014-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In the context of male osteoporosis, we hypothesize that regional changes in trabecular bone, as well as changes in cortical porosity will play a major role, and thus also affect bone strength. In developing therapeutics the response of individual compartments, regional variations post-therapy will have considerable impact on selecting the therapies as well as monitoring response to therapy. This study, a precursor to other therapeutic trials, will lay the ground-work for the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will recruit 80 subjects who will be stratified into groups based on their T-scores. All subjects will be imaged at Baseline and 12 months. Measures of bone micro-architecture in the tibia and radius using peripheral computed tomography, bone strength measures through finite element analysis will be obtained at all time points. DXA measures at the spine, femur and forearm will be obtained as reference measures. In addition whole body DXA scans will be performed for assessment of body composition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

osteoporosis and osteopenia

Subjects will be stratified based on DXA BMD T-scores.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men 50-85 years old
2. Patients must be willing to undergo a DXA scan.
3. Patients should be willing to undergo HRpQCT scan of the radius and tibia.

Exclusion Criteria

1. Inability to tolerate CT scans
2. Use of medications known to impact bone and mineral metabolism:

* use of a bisphosphonate or teriparatide in the last year or for \>12 months ever;
* current calcitonin;
* prednisone \>5 mg daily or the equivalent glucocorticoid for \>10 days in the last 3 months;
* current testosterone therapy;
* current thiazolidinedione (TZD);
* current androgen deprivation therapy;
* current use of an antiepileptic agent that alters hepatic vitamin D clearance;
* use of thyroid hormone replacement with current thyroid stimulating hormone \<0.1 mIU/L
3. Disease known to affect bone (e.g., primary hyperparathyroidism, Pagets disease, clinically significant liver disease)
4. Illicit drug use or alcohol use \>3 drinks/day
5. Serum calcium \>10.2 mg/dL or calculated creatinine clearance \<30 mL/min
6. Weight \>350 pounds (the maximum weight limit of the DXA)
7. Hardware in the lumbar spine
8. History of bilateral hip replacement, or bilateral wrist or ankle fracture

Minimum Eligible Age

50 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sharmila Majumdar, PhD

Role: PRINCIPAL_INVESTIGATOR

University of California, San Francisco

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCSF Imaging Center

San Francisco, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Majumdar #39637

Identifier Type: -

Identifier Source: org_study_id